DEC 23, 2015
Update on CXL in the United States
By Anat Galor, MD; Michael W. Belin, MD
AAO 2015
Cornea/External Disease
When will U.S. ophthalmologists finally get access to corneal collagen cross-linking? In this interview from AAO 2015, Dr. Michael Belin discusses this year’s controversial rejection of Avedro’s combined riboflavin ophthalmic solutions and ultraviolet light irradiation for corneal collagen cross-linking. Dr. Belin sits on the FDA’s Dermatologic and Ophthalmic Drugs Advisory Committee and Ophthalmic Devices Panel. He also discusses future prospects for this promising treatment.